BMO Capital Markets Raises PT on Isis; Vertex Up 57% Premarket After Positive Test Results Print E-mail
By Staff and Wire Reports   
Friday, 19 April 2013 18:35
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 19, 2013.

In a report BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised the price target from $22.00 to $31.00.

In the report, Birchenough noted, “The BMO Capital Markets US biotechnology team hosted a meeting this week with Isis Pharmaceuticals SVP of Clinical Development Dr. Richard Geary. Focus of the meeting was on a burgeoning pipeline of antisense oligonucleotide (ASO) therapeutics following recent approval of its first ASO therapeutic KYNAMRO.

With 28 different ASO therapeutics in development, primary focus was on key late stage programs including wholly owned ISISApoC3-Rx for severe triglyceride elevation as well as partnered programs for ISIS-SMN-Rx for spinal muscular atrophy (SMA) and TTR associated familial amyloid polyneuropathy (FAP).”

Isis Pharmaceuticals closed on Thursday at $19.41.


Vertex Pharmaceuticals (NASDAQ:VRTX)
now up 57% premarket after reporting positive test results last night. Previously bullish Deutsche raises its price target to $100 from $75, thinking the company could earn $10/share in 2015 and putting the stock's fair value as high as $150.

Goldman's on the case, upgrading to Hold from Sell and raising its price target to $86 from $38.

Also Friday:

BioTime, Inc. (NYSE MKT: BTX)
today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatment of stroke.

Cempra, Inc. (Nasdaq: CEMP)
today announced that it will report first quarter 2013 financial results and provide a business update after the close of U.S. financial markets on April 25, 2013.

today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's first quarter 2013 financial results on Friday, May 3 at 9:00 a.m. Eastern Time.

Health Enhancement Products (OTCBB: HEPI)
announces results of an ongoing bovine mastitis study conducted by Dr. Laura Hernandez, a lactation expert and faculty member at the University of Wisconsin-Madison.

InspireMD, Inc. (NYSE MKT: NSPR)
said Gwen K. Bame has joined the Company as Vice President of Corporate Development, reporting directly to Alan Milinazzo, President and CEO.

iTech Medical, Inc.  (PINKSHEETS: IMSU)
today announced that it has signed a non-binding letter of intent (the "LOI") with Ovid Capital Ventures, Inc., a corporation existing under the laws of Quebec ("Ovid"), which outlines the general terms and conditions pursuant to which iTech and Ovid would be willing to complete a transaction that will result in a merger of iTech and Ovid (the "Transaction"). The LOI was negotiated at arm's length and is effective as of April 18, 2013.

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH)
today announced results for the quarter ended March 31, 2013.

Novadaq® Technologies Inc. (TSX:NDQ)(NASDAQ:NVDQ)
, a developer of clinically-relevant fluorescence imaging solutions for use in surgical and wound care procedures, today announced that interim results from PILLARII, Perfusion Assessment in Laparoscopic Left Anterior Resection, were presented during the 2013 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting which is being held in Baltimore, MD from April 17-20.

Transgenomic, Inc. (OTCBB: TBIO)
today announced that it has been awarded the 2013 Governor’s Bioscience Award.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus